Apple Health PDL Drug Policy Motions



Endocrine and Metabolic Agents: Somatostatic Agents

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 30.17.00-1 as recommended.

Motion: Taylor

○ 2nd: Pope



Endocrine and Metabolic Agents: Vasopressin Receptor Antagonists – Oral

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 30.45.40-1 as recommended.

Motion: Hudson

2nd: Barkett



Endocrine and Metabolic Agents: Urea Cycle Disorder Agents- Oral

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 30.90.80-1 as recommended.

Motion: Barnes

2nd: Hudson



Oncology Agents: BRAF Kinase Inhibitors – Oral

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 21.53.20-1 as recommended.

Motion: Barkett

2nd: Weiland



Oncology Agents – Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 21.53.80.AA-1 as recommended.

Motion: Pope

○ 2nd: Barnes



Cytokine and CAM Antagonists: IL-36 Inhibitors

▶ Motion: I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 66.27.00.AL-1 as recommended.

Motion: Beste

○ 2nd: Hudson

